Latest News

Market cap$50M–$500B
SectorsAll
Filter by sector
Thursday, October 22, 2026· 9581 stock ideas· 219 writers·
23,411 views· 11,117 clicks

Lam Research Q1 FY6/27 Earnings Review

Lam Research reported $8.22 billion in Q1 FY6/27 revenue, with systems up 62% and operating margin reaching a record 40% as memory spending accelerated.

From X

@BrokenMoats 1 click

Broken Moats on X

$BFLY the Midjourney ultrasound full body announcement is a highly entertaining read. Sadly I cannot back into what the "ultrasound on a chip" pricing is and what 50,000 units * 40 chips would equate to at Midjourneys target opening in 2031 (as a potential full revenue opportunity). But I do know there are limitations in what ultrasound can scan for versus MRI/CT - their are advantageous for both and why they are used for different imaging needs (pregnancy, organ, blood flow for ultrasound v. skeletal, brain ct) ...So the companies promotion of using ultrasound pools to replace CT is either misleading or an outright lie, it is simply not possible. The story gets worse, they plan on opening spas, with water pools to conduct their scanning. Only doing body composition and no actual medical diagnosis scans to open in SF hopefully in 2027...the maintenance costs will be significant as they have to treat the water before each usage and limits throughput. Plus the renderings imply significant capX that will need to be recouped at some point (either throughput or higher prices than they are leading on). So no idea the propensity of vc funded AI companies to spend irrationally and without regard for economics so perhaps BFLY will be a beneficiary here (seems difficult at their current valuation and the likelihood of Midjourney ever scaling their operation but who knows....) the free spending train rolls on for now. I encourage someone to watch the videos put out by Midjourney its truly something......

Free Recaps of the best new stock ideas, delivered every morning.

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…

Have a source we’re missing? Send your pick

Recent recaps

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

90 accounts

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick